Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)

scientific article

Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study) is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2015PLoSO..1043643H
P356DOI10.1371/JOURNAL.PONE.0143643
P932PMC publication ID4669153
P698PubMed publication ID26633806
P5875ResearchGate publication ID285594973

P50authorHirokazu TaninoQ70967073
P2093author name stringTakashi Ishikawa
Yoshie Hasegawa
Norio Kohno
Daishu Miura
Jun Horiguchi
Kazuhiko Yamagami
Kouhei Akazawa
Masaru Miyashita
Masato Suzuki
Mitsuhiro Hayashi
Muneharu Konishi
Seung Jin Kim
Shintaro Takao
Tetsuya Taguchi
Tomoyuki Kubota
Yasushi Shigeoka
P2860cites workSafety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.Q53434420
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).Q54373964
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month resultsQ87419544
Development of bisphosphonatesQ21195188
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerQ24597847
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialQ30416847
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionQ33531646
Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancersQ34025648
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assayQ34348233
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.Q34943802
The backbone of progress--preclinical studies and innovations with zoledronic acidQ37847339
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.Q39822665
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.Q42603658
Breast-cancer adjuvant therapy with zoledronic acidQ42620139
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialQ43911264
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectzoledronic acidQ218507
chemotherapyQ974135
P304page(s)e0143643
P577publication date2015-01-01
P1433published inPLOS OneQ564954
P1476titleRandomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)
P478volume10

Reverse relations

cites work (P2860)
Q92910688Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Q47693752Bisphosphonates and other bone agents for breast cancer.
Q92848745Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis
Q88573696Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis
Q39375196Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Q98164813Repurposing of drugs for triple negative breast cancer: an overview
Q38733725The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.

Search more.